(FM) Medicina Interna
Departamento académico
Eduardo Carlos
Salido Ruiz
Publicaciones en las que colabora con Eduardo Carlos Salido Ruiz (11)
2024
-
Efficient and safe therapeutic use of paired Cas9-nickases for primary hyperoxaluria type 1
EMBO molecular medicine, Vol. 16, Núm. 1, pp. 112-131
2022
-
In vivo CRISPR-Cas9 inhibition of hepatic LDH as treatment of primary hyperoxaluria
Molecular Therapy - Methods and Clinical Development, Vol. 25, pp. 137-146
2021
-
Small molecule-based enzyme inhibitors in the treatment of primary hyperoxalurias
Journal of Personalized Medicine, Vol. 11, Núm. 2, pp. 1-31
2019
2018
-
CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I
Nature Communications, Vol. 9, Núm. 1
-
Erratum to “A new HDV mouse model identifies mitochondrial antiviral signaling protein (MAVS) as a key player in IFN-β induction” [J Hepatol 67 (2017) 669–679] (S0168827817320469) (10.1016/j.jhep.2017.05.010))
Journal of Hepatology
2017
-
A new HDV mouse model identifies mitochondrial antiviral signaling protein (MAVS) as a key player in IFN-β induction
Journal of Hepatology, Vol. 67, Núm. 4, pp. 669-679
2016
-
Generation and characterization of human iPSC lines derived from a Primary Hyperoxaluria Type I patient with p.I244T mutation
Stem Cell Research, Vol. 16, Núm. 1, pp. 116-119
-
Transient expression of transgenic IL-12 in mouse liver triggers unremitting inflammation mimicking human autoimmune hepatitis
Journal of Immunology, Vol. 197, Núm. 6, pp. 2145-2156
2012
2009
-
Bone marrow-derived cells promote liver regeneration in mice with erythropoietic Protoporphyria
Transplantation, Vol. 88, Núm. 12, pp. 1332-1340